share_log

泽璟制药(688266.SH):盐酸吉卡昔替尼片获得药物临床试验批准通知书

Zejing Pharmaceutical (688266.SH): Gicaxitinib hydrochloride tablets obtained drug clinical trial approval notice

Gelonghui Finance ·  May 29 04:11

Gelonghui, May 29丨Zejing Pharmaceutical (688266.SH) announced that the company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration. The phase II/III clinical trial of gikaxitinib hydrochloride tablets (formerly known as jacketinib hydrochloride tablets) to treat adolescents and adults aged 12 and above and patients with non-segmental vitiligo was approved.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment